A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Food Effects of a Single Oral VV119 Capsule in Healthy Chinese Volunteers
Latest Information Update: 18 Aug 2026
At a glance
- Drugs VV 119 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Vigonvita Life Sciences
Most Recent Events
- 14 Aug 2026 Planned End Date changed from 1 Dec 2025 to 1 Oct 2026.
- 14 Aug 2026 Planned primary completion date changed from 1 Dec 2025 to 1 Oct 2026.
- 14 Aug 2026 Status changed from recruiting to active, no longer recruiting.